Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OMTX705,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oncomatryx
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Oncomatryx will foster its leadership in ADCs targeting the tumor microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class ADC targeting cancer-...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 18, 2023
Lead Product(s) : OMTX705,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oncomatryx
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
